Updated:
MIRA Pharmaceuticals
MIRA Pharmaceuticals was formed as a publicly traded entity under the ticker MIRA on the Nasdaq Capital Market.
MIRA Pharmaceuticals
MIRA Pharmaceuticals was formed as a publicly traded entity under the ticker MIRA on the Nasdaq Capital Market. The company's wealth origin traces to its public listing and subsequent capital raises through equity offerings, rather than a family or private fortune. MIRA's strategy centers on developing synthetic cannabinoid and ketamine analogs for central nervous system disorders. Its pipeline includes MIRA-55 (oral ketamine analog for depression/anxiety) and PT-001 (synthetic THC analog for neuropathic pain). The company targets a $50B+ addressable market in neurological conditions, per its regulatory filings. As of 2025, MIRA Pharmaceuticals had a market capitalization below $50M and employed fewer than 15 full-time staff, per SEC filings. The firm operated out of a single office in the United States. In Q4 2024, MIRA announced positive topline results from a Phase 1 trial for MIRA-55. MIRA's structural differentiator is its focus on repurposing known drug mechanisms — ketamine for depression, cannabinoids for pain — into oral formulations with improved safety profiles. This approach reduces preclinical risk but still requires full clinical validation. The company's publicly traded structure imposes quarterly disclosure obligations and limits operational confidentiality.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Sector focus
Frequently asked questions
What is MIRA Pharmaceuticals' lead drug candidate?
MIRA-55 is the company's lead candidate — a synthetic oral ketamine analog designed to treat depression and anxiety. Phase 1 trials showed rapid antidepressant effects in healthy volunteers (per MIRA press release, 2024).
How is MIRA Pharmaceuticals funded?
MIRA is publicly traded on the Nasdaq under ticker MIRA. Its funding comes from equity offerings and government grants, not from a single family office or private wealth pool (per SEC filings).
What therapeutic areas does MIRA target?
MIRA focuses on neurological and neuropsychiatric disorders, including depression, anxiety, neuropathic pain, and cognitive decline. Its pipeline covers both central nervous system indications and pain management.
Who leads MIRA Pharmaceuticals?
As of 2025, MIRA's CEO and President is Dr. Erez Ben-Zvi, with Dr. Charles Nichols serving as Chief Scientific Officer. Key management is disclosed in SEC filings and corporate materials.
Does MIRA Pharmaceuticals collaborate with academic institutions?
MIRA has disclosed partnerships with the University of Texas at Austin and Louisiana State University Health Sciences Center for preclinical and early-stage research (per public contracts and press releases).
What is MIRA's regulatory strategy?
MIRA is pursuing FDA approval through standard clinical trial phases for both MIRA-55 (ketamine analog) and PT-001 (synthetic THC analog). The company targets a 505(b)(2) regulatory pathway for MIRA-55, which allows relying on existing safety data for ketamine (per SEC filings).
Is MIRA Pharmaceuticals a family office or investment vehicle?
No. MIRA is a publicly traded biopharmaceutical company. It is not structured as a family office, holding company, or investment fund — it operates as a standard clinical-stage drug developer.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: